Improving Localized Radiotherapy for Glioblastoma via Small Molecule Inhibition of KIF11

Area of Science:

• Neuro-oncology
• Cancer Biology
• Radiation Oncology

Background:

• Glioblastoma (IDH-wild type) is a lethal brain tumor with poor survival rates.
• Current standard treatments (surgery, radiotherapy, temozolomide) offer limited efficacy.
• Glioblastoma exhibits significant radioresistance, necessitating novel therapeutic strategies.

Purpose of the Study:

• To investigate if cell cycle synchronization in mitosis can enhance radiotherapy for glioblastoma.
• To evaluate the efficacy of ispinesib, a KIF11 inhibitor, in radiosensitizing glioblastoma cells.
• To assess the combination therapy of ispinesib and irradiation in preclinical models.

Main Methods:

• Utilized ispinesib to induce mitotic arrest in patient-derived glioblastoma cells.
• Performed cell culture studies to assess radiosensitization.
• Conducted in vivo experiments to evaluate tumor cell mitosis, apoptosis, and survival in combination therapy models.

Main Results:

• Ispinesib effectively induced mitotic arrest and radiosensitized glioblastoma cells in vitro.
• In vivo, ispinesib increased mitotic arrest and apoptosis in tumor cells.
• Combination therapy with ispinesib and irradiation demonstrated superior survival benefit compared to monotherapy.

Conclusions:

• KIF11 inhibition via ispinesib enhances glioblastoma cell sensitivity to radiotherapy.
• The combination of ispinesib and irradiation represents a novel therapeutic approach for glioblastoma.
• This strategy shows potential for clinical translation to improve glioblastoma treatment outcomes.